Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LGMN | Q99538 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351767 | 0.93 | AGXT (0.46) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL12635871 | 0.89 | ST14 (0.52) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL12294725 | 0.87 | HRH3 (0.48) | LMNAALDH1A1MAPTHTTKMT2A | |
| SCHEMBL1239752 | 0.84 | MAPT (0.55) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL2187269 | 0.84 | SLC13A5 (0.49) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL108136 | 0.83 | AGXT (0.69) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL7365166 | 0.83 | CHKA (0.50) | ALDH1A1MAPTRAB9AHTTMEN1 | |
| SCHEMBL112580 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTRAB9AHTTMEN1 | |
| Hydrochloric Acid SCHEMBL21382220 | 0.82 | SLC13A5 (0.48) | LMNAALDH1A1MAPTRAB9AHTT | |
| SCHEMBL3722035 | 0.82 | AOC3 (0.62) | LMNAALDH1A1MAPTRAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016087603-A1 | PROCESS FOR PREPARING A MODIFIED NATURAL RUBBER BY MEANS OF A MODIFIER | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2016-06-09 | — | — | WO | claimed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | claimed |
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | claimed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | claimed |
| US-20030212069-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-11-13 | — | — | US | claimed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | claimed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | claimed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | claimed |
| EP-1140881-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039111-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ORIGIANT PHARMACEUTICAL CO., LTD (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | disclosed |
| EP-1140881-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039111-A1 | ANTITHROMBOTIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | LMNA 2251/4885ALDH1A1 2743/4885MAPT 4544/4885 |
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | LMNA 2465/4885ALDH1A1 404/4885MAPT 4597/4885 |
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | RIPK1, RIPK3, RIPK2 | LMNA 3352/4885ALDH1A1 3976/4885MAPT 1137/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | LMNA 2465/4885ALDH1A1 404/4885MAPT 4597/4885 |
| US-20030212069-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | LMNA 2465/4885ALDH1A1 404/4885MAPT 4597/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | LMNA 2916/4885ALDH1A1 2373/4885MAPT 4640/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | LMNA 3945/4885ALDH1A1 4309/4885MAPT 3342/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | LMNA 2465/4885ALDH1A1 404/4885MAPT 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.